Lactobacillus reuteri attenuates cardiac injury without lowering cholesterol in low-density lipoprotein receptor-deficient mice fed standard chow
- 15 May 2020
- journal article
- research article
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 319 (1) , H32-H41
Abstract
Disruption of the normal gut microbiome (dysbiosis) is implicated in the progression and severity of myriad disorders, including hypercholesterolemia and cardiovascular disease. Probiotics attenuate and reverse gut dysbiosis to improve cardiovascular risk factors like hypertension and hypercholesterolemia. Lactobacillus reuteri is a well-studied lactic acid-producing probiotic with known cholesterol-lowering properties and anti-inflammatory effects. In the present study, we hypothesized that L. reuteri delivered to hypercholesterolemic low-density lipoprotein receptor knock-out (LDLr KO) mice will reduce cholesterol levels and minimize cardiac injury from an ischemic insult. L. reuteri (1x109 or 50x106 CFU/day) was administered by oral gavage to wild type mice and LDLr KO for up to 6 weeks followed by an ischemia-reperfusion (I/R) protocol. After 4 weeks of gavage, total serum cholesterol in wild type mice receiving saline was 113.5±5.6 mg/dl compared to 113.3±6.8 mg/dl and 101.9±7.5 mg/dl in mice receiving 1x109 or 50x106 CFU/day, respectively. Over the same timeframe, administration of L. reuteri at 1x109 or 50x106 CFU/day did not lower total serum cholesterol (283.0±11.1, 263.3±5.0 and 253.1±7.0 mg/dl; Saline, 1x109 or 50x106 CFU/day, respectively) in LDLr KO mice. Despite no impact on total serum cholesterol, L. reuteri administration significantly attenuated cardiac injury following I/R, as evidenced by smaller infarct sizes when compared to controls in both wild type and LDLr KO groups. In conclusion, daily L. reuteri significantly protected against cardiac injury without lowering cholesterol levels suggesting anti-inflammatory properties of L. reuteri uncoupled from improvements in serum cholesterol.Keywords
Funding Information
- HHS | National Institutes of Health (R01 HL098256, K01 AR052840, GM004905, HL007249, K02 HL105799, HL00795515)
- American Heart Association (16GRNT31390006)
- Sarver Heart Center at University of Arizona
- Steven M. Gootter Foundation
This publication has 55 references indexed in Scilit:
- Oral administration of Lactobacillus reuteri GMNL-263 improves insulin resistance and ameliorates hepatic steatosis in high fructose-fed ratsNutrition & Metabolism, 2013
- Symptomatic atherosclerosis is associated with an altered gut metagenomeNature Communications, 2012
- Optimizing Dynamic Interactions between a Cardiac Patch and Inflammatory Host CellsCells Tissues Organs, 2011
- Lecithin Cholesterol Acyltransferase Null Mice Are Protected from Diet-induced Obesity and Insulin Resistance in a Gender-specific Manner through Multiple PathwaysJournal of Biological Chemistry, 2011
- Impaired Infarct Healing in Atherosclerotic Mice With Ly-6ChiMonocytosisJACC, 2010
- PrimerBank: a resource of human and mouse PCR primer pairs for gene expression detection and quantificationNucleic Acids Research, 2009
- Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43Nature, 2009
- The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functionsJournal of Experimental Medicine, 2007
- Obesity alters gut microbial ecologyProceedings of the National Academy of Sciences, 2005
- Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery.Journal of Clinical Investigation, 1993